All news

B.Riley slashes Cue Biopharma target to $25

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

B.Riley cut its Cue Biopharma price target to $25 from $83 while keeping a Buy rating, citing multi-year financing challenges. The stock has fallen 84.83% over the past week, leaving a market cap of $20.56 million, which the firm considers excessive given unchanged clinical efficacy results for CUE-221. All three covering analysts rate it Buy.

Read original source

CUE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.